提示: 手机请竖屏浏览!

注意缺陷多动障碍的药物治疗
Pharmacologic Treatment of Attention Deficit–Hyperactivity Disorder


Samuele Cortese ... 其他 • 2020.09.10

注意缺陷多动障碍(ADHD)的特征包括多动、冲动、注意力不集中,或者是多动、冲动和注意力不集中的组合,并且这些表现与发育水平不符,且影响日常功能1。该疾病通常在儿童期诊断出,并且在多达70%的儿童期病例中,导致功能损害的症状会持续至成年期2

ADHD患者的治疗包括药物治疗、非药物治疗或这两者的联合治疗。美国食品药品管理局(FDA)批准的药物包括兴奋剂(苯丙胺和哌甲酯)和非兴奋剂(托莫西汀、可乐定缓释剂和胍法辛[guanfacine]缓释剂)(表1)。兴奋剂通常被推荐作为一线药物治疗(表2)。自从1937年报道苯丙胺化合物对ADHD症状的正面影响,以及1955年FDA批准哌甲酯以来,已发表多项关于ADHD药物治疗的研究。本综述总结了已获监管机构批准的ADHD治疗药物的最新证据,但文中未探讨使用这些药物的合理性或不合理性。





作者信息

Samuele Cortese, M.D., Ph.D.
From the Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, and Solent NHS Trust, Southampton, and the Division of Psychiatry and Applied Psychology, Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham — all in the United Kingdom; and the Department of Child and Adolescent Psychiatry, New York University Grossman School of Medicine, New York. Address reprint requests to Dr. Cortese at the Centre for Innovation in Mental Health, University of Southampton, Highfield Campus, Bldg. 44, Southampton, SO17 1BJ, United Kingdom, or at samuele.cortese@soton.ac.uk.

 

参考文献

1. Feldman HM, Reiff MI. Attention deficit–hyperactivity disorder in children and adolescents. N Engl J Med 2014;370:838-846.

2. Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 2015;1:15020-15020.

3. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2019;144(4):e20192528-e20192528.

4. National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. March 14, 2018 (https://www.nice.org.uk/guidance/NG87. opens in new tab).

5. Association of the Scientific Medical Societies in Germany (AWMF). Interdisciplinary evidence- and consensus-based (S3) guideline “Attention deficit/hyperactivity disorder in children, young people and adults.” 2018. (In German) (https://www.awmf.org/uploads/tx_szleitlinien/028-045l_S3_ADHS_2018-06.pdf. opens in new tab).

6. Raman SR, Man KKC, Bahmanyar S, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry 2018;5:824-835.

7. Polanczyk GV, Willcutt EG, Salum GA, Kieling C, Rohde LA. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 2014;43:434-442.

8. Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder — a systematic literature review. Neuropsychiatr Dis Treat 2014;10:1543-1569.

9. Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand 2013;128:70-77.

10. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727-738.

11. Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012;200:97-106.

12. Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord 2000;3:200-211.

13. Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H. Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 2019;86:335-343.

14. Matthijssen A-FM, Dietrich A, Bierens M, et al. Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatry 2019;176:754-762.

15. Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2017;26:1283-1307.

16. Tsujii N, Okada T, Usami M, et al. Effect of continuing and discontinuing medications on quality of life after symptomatic remission in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Clin Psychiatry 2020;81:19r13015-19r13015.

17. Cortese S, Holtmann M, Banaschewski T, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54:227-246.

18. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol 2013;23:534-541.

19. Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 2012;169:167-177.

20. Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psychiatry 2019;28:1283-1293.

21. Poulton A. Growth on stimulant medication: clarifying the confusion: a review. Arch Dis Child 2005;90:801-806.

22. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:919-927.

23. Greenhill LL, Swanson JM, Hechtman L, et al. Trajectories of growth associated with long-term stimulant medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2020;59:978-989.

24. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:994-1009.

25. Li L, Sujan AC, Butwicka A, et al. Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS Drugs 2020;34:731-747.

26. Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J. Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Biol Psychiatry 2014;76:616-628.

27. Liddle EB, Hollis C, Batty MJ, et al. Task-related default mode network modulation and inhibitory control in ADHD: effects of motivation and methylphenidate. J Child Psychol Psychiatry 2011;52:761-771.

28. Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 2013;70:185-198.

29. Hoogman M, Muetzel R, Guimaraes JP, et al. Brain imaging of the cortex in ADHD: a coordinated analysis of large-scale clinical and population-based samples. Am J Psychiatry 2019;176:531-542.

30. Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH. Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies. J Am Acad Child Adolesc Psychiatry 2020;59:100-112.

服务条款 | 隐私政策 | 联系我们